• 1
    Weiss SW, Goldblum J. Malignant soft tissue tumors of uncertain type. In: WeissSW, GoldblumJR, editors. Enzinger and Weiss's soft tissue tumors. St. Louis: CV Mosby, 2001: 14831571.
  • 2
    Miser JS, Pappo AS, Triche TJ, et al. Other soft tissue sarcomas of childhood. In: PizzoPA, PoplackDG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins, 2002: 10171050.
  • 3
    Ladenstein R, Treuner J, Koscielniak E, et al. Synovial sarcoma of childhood and adolescence: report of the German CWS-81 study. Cancer. 1993; 71: 36473655.
  • 4
    Ferrari A, Casanova M, Massimino M, et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol. 1999; 32: 3237.
  • 5
    Pappo AS, Fontanesi J, Luo X, et al. Synovial sarcoma in children and adolescents: the St. Jude Children's Research Hospital experience. J Clin Oncol. 1994; 12: 23602366.
  • 6
    Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003; 21: 16021611.
  • 7
    Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian Randomized Cooperative Trial. J Clin Oncol. 2001; 19: 12381247.
  • 8
    Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997; 350: 16471654.
  • 9
    Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localised soft-tissue sarcoma in adults. Cochrane Database Syst Rev. 2000; 2: CD001419.
  • 10
    Brodsky JT, Burt ME, Hajdu SI, et al. Tendosynovial sarcoma: clincopathologic features, treatment and prognosis. Cancer. 1992; 70: 484489.
  • 11
    Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999; 85: 25962607.
  • 12
    Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000; 18: 20872094.
  • 13
    Spillane AJ, A'Hern R, Judson IR, et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000; 18: 37943803.
  • 14
    Trassard M, Le Doussal V, Hacène K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001; 19: 525534.
  • 15
    Mancuso T, Mezzekani A, Riva C, et al. Analysis of SYT-SSX fusion transcripts and bcl-2 expression phosphorylation status in synovial sarcoma. Lab Invest. 2000; 80: 805813.
  • 16
    Mezzelani A, Mariani L, Tamborini E, et al. SYT-SSX fusion genes and prognosis in synovial sarcoma. Br J Cancer. 2001; 85: 15351539.
  • 17
    Tamborini E, Bonadiman L, Greco A, et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor β tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res. 2004; 10: 938943.
  • 18
    HarmerMH, editor. TNM classification of pediatric tumors. Geneva: International Union Against Cancer, 1982.
  • 19
    Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study I: a final report. Cancer. 1988; 61: 209220.
  • 20
    Wunder JS, Healey JH, Davis AM, Brennan MF. A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer. 2000; 88: 27212730.
  • 21
    Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 1980; 153: 106120.
  • 22
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 23
    Bramwell VH. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol. 2001; 19: 12351237.
  • 24
    Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11: 12691275.
  • 25
    Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue Sarcoma and Bone Sarcoma Group. J Clin Oncol. 1994; 12: 11371149.
  • 26
    Antman K, Crowley J, Balcerzak SP, et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11: 12761285.
  • 27
    Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology. 2003; 65: 8084.
  • 28
    Demetri GD. Highlights of sarcoma research. J Clin Oncol Classic Papers Curr Comments. 2002; 7: 681684.
  • 29
    Kampe CE, Rosen G, Eilber F, et al. Synovial sarcoma: a study of intensive chemotherapy in 14 patients with localized disease. Cancer. 1993; 72: 21612169.
  • 30
    Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer. 1994; 73: 25062511.